Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity

Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramaticall...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaoxiao, Wang, Hanping, Zhou, Jiaxin, Li, Yue, Duan, Lian, Si, Xiaoyan, Zhang, Li, Fang, Ligang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996973/
https://www.ncbi.nlm.nih.gov/pubmed/31849171
http://dx.doi.org/10.1111/1759-7714.13250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996973/
https://www.ncbi.nlm.nih.gov/pubmed/31849171
http://dx.doi.org/10.1111/1759-7714.13250

Ejemplares similares